NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

MeSH terms

• Antibodies, Monoclonal, Humanized / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / economics
• Antineoplastic Combined Chemotherapy Protocols / standards
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Bevacizumab
• Carboplatin / administration & dosage
• Cost-Benefit Analysis
• Deoxycytidine / administration & dosage
• Deoxycytidine / analogs & derivatives
• Drug Costs
• Female
• Gemcitabine
• Humans
• Neoplasm Recurrence, Local / drug therapy*
• Neoplasm Recurrence, Local / economics
• Neoplasm Recurrence, Local / mortality
• Neoplasm Recurrence, Local / pathology
• Ovarian Neoplasms / drug therapy*
• Ovarian Neoplasms / economics
• Ovarian Neoplasms / mortality
• Ovarian Neoplasms / pathology
• Practice Guidelines as Topic
• Quality-Adjusted Life Years
• Survival Analysis
• Time Factors
• Treatment Outcome